AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...

Impact of Demodex Blepharitis on Patients: Results of the Atlas Trial (ASCRS Paper ID 81946); Mitchell A. Jackson, M.D., et al.

SHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. “We know that many patients struggle with eyelid ...

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan ...

Waking up with some gunk in your eyes is usually nothing to worry about. The scientific name for this crust is rheum, and it forms when oil and other debris collect on your eyelids during sleep. But ...